Utilizing automated image analysis technology that identifies tumor and benign tissues, ProMark measures the quantitative expression levels of eight protein biomarkers that individually correlate with tumor aggressiveness and together predict your individual patient’s risk of aggressive disease.
This unique approach allows ProMark to outperform conventional gene expression-based diagnostic assays.
- A ProMark risk score provides a personalized prediction independent of clinical and pathological characteristics.
- In addition, when combined with existing risk stratification methods, ProMark provides additional information to support improved clinical decision-making.
Unlike genomic-based tests that require pathologists to indicate the areas of tumors, ProMark technology allows for analysis of proteins, a more direct reflection of biologic activity, directly from the cancerous regions of interest. There is no need for micro dissection and homogenization of tissue.
Blume-Jensen, P. et al. Development and Clinical Validation of an in situ Biopsy Based Multi-Marker Assay for Risk Stratification in Prostate Cancer. Clinical Cancer Research, doi:10.1158/1078-0432.ccr-14-2603 (2015).
Shipitsin, M. et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. British journal of cancer 111,
1201-1212, doi:10.1038/bjc.2014.396 (2014).
Shipitsin, M. et al. Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality.
Proteome science 12, 40, doi:10.1186/1477-5956-12-40 (2014).
Choudhury, S. et al. Evaluation of early clinical experience of a novel prognostic proteomics prostate cancer biopsy test. ASCO 2015 Genitourinary Cancers Symposium. (2015).